General Information of Drug (ID: DMQYLGP)

Drug Name
Levocetirizine
Synonyms
(-)-Cetirizine; (-)-Cetirizine Dihydrochloride; (2-(4-((R-p-Chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid; (2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; (R)-2-(2-(4-((4-Chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)acetic acid; (R)-Cetirizine dihydrochloride; 6U5EA9RT2O; Acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-; Levocetirizine; Levocetirizine HCl; UNII-6U5EA9RT2O; Xarlin; Xyzal; cetirizine-d4; levocetrizine
Indication
Disease Entry ICD 11 Status REF
Allergic rhinitis CA08.0 Approved [1]
Seasonal allergic rhinitis CA08.01 Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 388.892
Logarithm of the Partition Coefficient (xlogp) 1.7
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 2.31 +/- 0.50 mgh/L [2]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 0.27 +/- 0.0 4 mg/L [2]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 0.75 +/- 0.50 h [2]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Clearance
The clearance of drug is 0.57 +/- 0.18 mL/min/kg [2]
Elimination
168 hours post dose an average of 85.4% of a radiolabeled dose was recovered with an average of 80.8% in the urine and 9.5% in the feces [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 7.05 +/- 1.54 hours [2]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.1837 micromolar/kg/day [4]
Vd
The volume of distribution (Vd) of drug is 0.33 +/- 0.02 L/kg [2]
Water Solubility
The ability of drug to dissolve in water is measured as 0.101 mg/mL [3]
Chemical Identifiers
Formula
C21H25ClN2O3
IUPAC Name
2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid
Canonical SMILES
C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
InChI
InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)/t21-/m1/s1
InChIKey
ZKLPARSLTMPFCP-OAQYLSRUSA-N
Cross-matching ID
PubChem CID
1549000
ChEBI ID
CHEBI:94559
CAS Number
130018-77-8
DrugBank ID
DB06282
VARIDT ID
DR01302
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporter 4 (SLC22A11) DT06JWZ S22AB_HUMAN Substrate [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Levocetirizine FDA Label
2 Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. Eur J Clin Pharmacol. 2001 Oct;57(8):571-82.
3 BDDCS applied to over 900 drugs
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Cellular Uptake of Levocetirizine by Organic Anion Transporter 4. J Pharm Sci. 2017 Sep;106(9):2895-2898.